相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
Wenyan Zhong et al.
BMC GENOMICS (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
Ganjun Yu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients' response to cancer immunotherapy
Hany A. Omar et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance
Jinqi Liu et al.
PLOS ONE (2019)
A phase Ia/Ib, open label, multicenter, dose -escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
Curtis Robert Chong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
Drew W. Rasco et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Rational design of anti-GITR-based combination immunotherapy
Roberta Zappasodi et al.
NATURE MEDICINE (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RAS: Striking at the Core of the Oncogenic Circuitry
Ryan C. Gimple et al.
FRONTIERS IN ONCOLOGY (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles et al.
NATURE MEDICINE (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Trametinib in the treatment of multiple malignancies harboring MEK1 mutations
Tong Lian et al.
CANCER TREATMENT REVIEWS (2019)
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
Mai F. Tolba et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Branched-chain amino acid metabolism in cancer
Elitsa A. Ananieva et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2018)
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy
Minan Wang et al.
FASEB JOURNAL (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Michael S. Magee et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Xin Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function
Sairy Hernandez et al.
CELL REPORTS (2018)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Discovery of 4-((3′R,4′S,5′R)-6-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
Angelo Aguilar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Giovanni Germano et al.
NATURE (2017)
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
Giulia Martini et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau et al.
NATURE COMMUNICATIONS (2017)
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Rona Yaeger et al.
CANCER RESEARCH (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity
Gang Guo et al.
CANCER RESEARCH (2017)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff et al.
CLINICAL CANCER RESEARCH (2016)
KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer
Karen Bento Ribeiro et al.
CANCER BIOMARKERS (2016)
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Pu Yan et al.
CLINICAL CANCER RESEARCH (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Acquisition of anticancer drug resistance is partially associated with cancer sternness in human colon cancer cells
Flaria El Khoury et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin
Yi-Hu Zheng et al.
LIVER INTERNATIONAL (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma
Meng Xu et al.
ONCOLOGY LETTERS (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Do-Youn Oh et al.
CANCER RESEARCH AND TREATMENT (2016)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
Piotr Donizy et al.
DIAGNOSTIC PATHOLOGY (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors
Xue-Yan He et al.
CELL REPORTS (2015)
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma
Dae-Woon Eom et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
Colorectal cancer
Ernst J. Kuipers et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
John C. Castle et al.
BMC GENOMICS (2014)
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model
Chang Hoon Moon et al.
INVESTIGATIONAL NEW DRUGS (2014)
Branched-chain amino acids in metabolic signalling and insulin resistance
Christopher J. Lynch et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma
Wen Zhou et al.
MOLECULAR CANCER (2013)
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Martje Toenjes et al.
NATURE MEDICINE (2013)
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
J. B. Bachet et al.
ANNALS OF ONCOLOGY (2012)
HPK1 as a novel target for cancer immunotherapy
Sansana Sawasdikosol et al.
IMMUNOLOGIC RESEARCH (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation
Remi Lasserre et al.
JOURNAL OF CELL BIOLOGY (2011)
Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog
Jaekwang Lee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita et al.
CLINICAL CANCER RESEARCH (2010)
Regulatory T cells in tumor immunity
Hiroyoshi Nishikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors
Jaekwang Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
AVE8062: a new combretastatin derivative vascular disrupting agent
Angelo Delmonte et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling
Hiroyoshi Nishikawa et al.
CANCER RESEARCH (2008)
Glucocorticoid-induced TNFR-Related protein lowers the threshold of CD28 costimulation in CD8+ T cells
Simona Ronchetti et al.
JOURNAL OF IMMUNOLOGY (2007)
Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses
Jr-Wen Shui et al.
NATURE IMMUNOLOGY (2007)
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
KR Hande et al.
CLINICAL CANCER RESEARCH (2006)
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
LV Beerepoot et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration?
GWM Swart et al.
CANCER AND METASTASIS REVIEWS (2005)
Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells
F Kanamaru et al.
JOURNAL OF IMMUNOLOGY (2004)
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
JP Stevenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
Molecular basis for the hemophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction
LCLT van Kempen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
